Search Results

You are looking at 21 - 30 of 91 items for :

  • "cytoreduction" x
  • Refine by Access: All x
Clear All
Full access

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Joyce Liu, Haider Mahdi, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

, initial surgery should include a hysterectomy (if uterus present) and bilateral salpingo-oophorectomy (BSO) with comprehensive staging and debulking as indicated. 5 , 16 , 17 This is the recommended approach for stage IA–IV if optimal cytoreduction

Full access

Practicing What We Preach!

Robert J. Morgan Jr

setting after surgical cytoreduction. The initial trial was published in December 1996, 3 and compared treatment with intravenous cyclophosphamide and intravenous cisplatin versus intravenous cyclophosphamide and intraperitoneal cisplatin. Results showed

Full access

Ovarian Cancer, Version 2.2013

Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer, and Miranda Hughes

reproduced in any form without the express written permission of NCCN®. IP Chemotherapy Surgical cytoreduction (debulking) is recommended as initial treatment for many women with ovarian cancer, even those with metastatic disease. 8 - 13 After

Full access

Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer

Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen

outcome is related primarily to underlying biology or aggressive cytoreduction with or without hyperthermic intraperitoneal chemotherapy is still debated. The role of modern systemic chemotherapy and targeted therapy in early or advanced nonmucinous and

Full access

Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Presented by: Joyce F. Liu

best outcomes have been reported when upfront surgery that leaves no residual disease can be achieved, 3 – 5 and upfront surgery should be considered for patients in whom optimal cytoreduction can be safely achieved. For this reason, it is important

Full access

Additional Abstracts from the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™

treatment efficacy of sorafenib in patients with HCC. AB2016-31. Clinical Values of Serum CA-125 and Human Epididymis Protein 4 in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced-Stage Ovarian Carcinoma Shiv Rajan, MCh, MS a

Full access

Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis

Zi-Xian Wang, Hao-Xiang Wu, Ming-Ming He, Ying-Nan Wang, Hui-Yan Luo, Pei-Rong Ding, Dan Xie, Gong Chen, Yu-Hong Li, Feng Wang, and Rui-Hua Xu

that anti-EGFR agents are worthy of consideration for patients with RAS wt right-sided tumors when cytoreduction is set as the therapeutic goal. A previous study showed a strong correlation between ORR and the R0 resection rate among patients with

Full access

Epithelial Ovarian Cancer

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner

and cytoreduction, followed by systemic chemotherapy in most patients. Initial surgery should consist of a comprehensive staging laparotomy, including a total abdominal hysterectomy and bilateral salpingo-oophorectomy. Based on published improved

Full access

Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes

Rafael Bejar

, investigators actually observed cytoreduction of the TP53 -mutant clone,” said Dr. Bejar. “This suggests that if the transplant is timed appropriately after treatment, patients might have less residual disease and may have a longer time to relapse, allowing

Full access

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022

Featured Updates to the NCCN Guidelines

Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, John M. Bennett, Uma Borate, Andrew M. Brunner, Wanxing Chai-Ho, Peter Curtin, Carlos M. de Castro, H. Joachim Deeg, Amy E. DeZern, Shira Dinner, Charles Foucar, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Brian A. Jonas, Sioban Keel, Yazan Madanat, Lori J. Maness, James Mangan, Shannon McCurdy, Christine McMahon, Bhumika Patel, Vishnu V. Reddy, David A. Sallman, Rory Shallis, Paul J. Shami, Swapna Thota, Asya Nina Varshavsky-Yanovsky, Peter Westervelt, Elizabeth Hollinger, Dorothy A. Shead, and Cindy Hochstetler

/2 inhibitors for cytoreduction in patients with high-risk MDS 17 , 19 refractory to HMAs (see MDS-6A , above). When used as cytoreduction for MDS in combination with an HMA, venetoclax has been effectively given for 14 days in monthly courses. 17 Repeating